TD Cowen lowered the firm’s price target on NGM Biopharmaceuticals to $4 from $9 and keeps an Outperform rating on the shares. The firm noted investor focus remains on the myeloid checkpoint inhibitor programs NGM707 831 and 438 currently in Ph1/2 signal finding studies and expected to generate initial data to identify potential target tumor profiles.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NGM:
- NGM Biopharmaceuticals reports Q3 EPS (35c), consensus (42c)
- NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
Questions or Comments about the article? Write to editor@tipranks.com